Neovascular Age‑Related Macular Degeneration (nAMD)

Overview

Neovascular age‑related macular degeneration (nAMD), also called “wet” AMD, is a chronic, progressive eye disease that damages the macula—the central part of the retina responsible for sharp, straight‑ahead vision. In nAMD, abnormal blood vessels grow beneath the macula, leak fluid, and cause scar tissue, leading to rapid central vision loss.

Who it affects: nAMD most commonly occurs in people aged 60 years and older, and it is far more prevalent in individuals of European ancestry, though it can affect any ethnic group.

Prevalence: In the United States, approximately 1.8 million people have AMD, and about 10–15 % of those have the neovascular (wet) form.^{[1] Mayo Clinic} Worldwide, AMD is the leading cause of irreversible vision loss in adults over 50, accounting for an estimated 8.7 % of all visual impairment.^{[2] WHO}

Symptoms

Symptoms can develop suddenly or progress over weeks. Early detection is critical because timely treatment can preserve vision.

• Blurred or distorted central vision – Straight lines may appear wavy (metamorphopsia).
• Dark or empty spot in the center of the visual field – Often described as a “hole” or “scotoma.”
• Decreased ability to see colors – Colors may look faded or washed out.
• Reduced contrast sensitivity – Difficulty distinguishing subtle shades.
• Difficulty reading, recognizing faces, or performing fine tasks – Tasks that rely on central vision become challenging.
• Visual hallucinations (Charles Bonnet syndrome) – Uncommon but possible in advanced disease.

Causes and Risk Factors

Underlying Pathophysiology

In nAMD, inflammatory and oxidative stress damage the retinal pigment epithelium (RPE). This triggers the release of vascular endothelial growth factor (VEGF), which stimulates the growth of fragile, leaky choroidal neovascular membranes (CNV) beneath the macula. The ensuing fluid and hemorrhage disrupt the photoreceptors, leading to vision loss.

Key Risk Factors

• Age: Risk sharply rises after 60 years.
• Genetics: Variants in the CFH, ARMS2, and HTRA1 genes increase susceptibility.^{[3] NIH}
• Smoking: Current smokers have a 2–3‑fold higher risk.^{[4] CDC}
• Race/Ethnicity: Higher prevalence in people of Caucasian descent; lower in African American and Asian populations.
• Family History: First‑degree relatives with AMD double the risk.
• Cardiovascular disease & hypertension – Shared vascular pathways may accelerate CNV formation.
• Obesity & high‑fat diet – Linked to systemic inflammation.
• Excessive sunlight exposure – Cumulative UV/blue‑light exposure may damage the RPE.

Diagnosis

Because early nAMD may be subtle, a comprehensive eye exam is essential for anyone over 50 with visual changes.

Clinical Examination

• Visual acuity testing – Determines the level of central vision loss.
• Amsler grid – Patients look at a grid to detect distortion or missing areas.
• Dilated fundus examination – Allows the ophthalmologist to view the macula directly.

Imaging Tests

• Optical Coherence Tomography (OCT) – Provides cross‑sectional images of retinal layers, showing fluid, thickening, or sub‑retinal scar.^{[5] Cleveland Clinic}
• Fluorescein Angiography (FA) – Dye injected into a vein highlights leaking neovascular membranes.
• Indocyanine Green Angiography (ICGA) – Better for visualizing deeper choroidal vessels.
• Fundus Autofluorescence (FAF) – Detects RPE stress before overt lesions appear.

Diagnosis is usually confirmed by OCT together with FA or ICGA showing atypical leakage.

Treatment Options

While nAMD cannot be cured, modern therapies can halt progression and often improve vision.

Anti‑VEGF Intravitreal Injections

These are the cornerstone of treatment.

• Aflibercept (Eylea) – Administered every 8 weeks after three monthly loading doses.
• Ranibizumab (Lucentis) – 4‑weekly loading then pro‑re nata (PRN) or treat‑and‑extend.
• Bevacizumab (Avastin) – Off‑label but widely used because of lower cost; similar schedule.
• Brolucizumab (Beovu) – May allow 12‑week intervals for some patients but carries a rare risk of intraocular inflammation.

Clinical trials show that >90 % of patients maintain or gain ≥15 letters (≈3 lines) of vision after 2 years of consistent anti‑VEGF therapy.^{[6] NEI}

Photodynamic Therapy (PDT)

Verteporfin‑mediated PDT is reserved for polypoidal choroidal vasculopathy or when anti‑VEGF alone is insufficient. The drug is activated by a non‑thermal laser, selectively closing abnormal vessels.

Surgical Options (Rare)

• Sub‑macular surgery – Removal of sub‑retinal hemorrhage or scar; high risk, used only in select cases.
• Vitrectomy with gas tamponade – May be considered for large, dense hemorrhages.

Lifestyle & Adjunctive Measures

• AREDS2 supplement regimen – High‑dose antioxidant vitamins (vitamins C, E), zinc, copper, and lutein/zeaxanthin; shown to reduce progression of intermediate AMD to advanced forms.^{[7] JAMA Ophthalmology}
• Blood pressure and cholesterol control – Reduces systemic vascular stress.
• Smoking cessation – Critical for slowing disease activity.
• UV/blue‑light blocking eyewear – May protect remaining RPE cells.

Living with Neovascular Age‑Related Macular Degeneration

Daily Management Tips

• Adhere to injection schedules – Missing appointments can lead to irreversible vision loss.
• Use low‑vision aids – Magnifiers, high‑contrast reading glasses, and electronic devices (e.g., screen readers).
• Optimize lighting – Bright, glare‑free lighting reduces strain.
• Maintain a structured environment – Keep furniture and objects in consistent locations to avoid accidents.
• Stay physically active – Improves cardiovascular health and may slow progression.
• Regular follow‑up – Even if vision is stable, at least biannual retinal imaging is recommended.

Emotional & Social Support

Vision loss can cause anxiety, depression, and social isolation. Encourage patients to:

• Connect with low‑vision rehabilitation services.
• Join support groups (e.g., Macular Degeneration Foundation).
• Consider counseling or mental‑health referrals if needed.

Prevention

While age and genetics are non‑modifiable, several evidence‑based strategies can lower the risk of developing nAMD or slowing its progression.

• Consume a Mediterranean‑style diet rich in leafy greens, fatty fish, nuts, and olive oil.
• Take AREDS2‑formulated supplements if you have intermediate AMD or a strong family history.
• Quit smoking and limit exposure to secondhand smoke.
• Control systemic conditions – Keep blood pressure <130/80 mmHg and LDL cholesterol <100 mg/dL.
• Regular eye exams – Annual dilated exams after age 50; earlier if risk factors are present.
• Protect eyes from UV/blue light – Wear sunglasses with 99 % UV protection and consider blue‑light filtering lenses.

Complications

If nAMD is not treated promptly, several serious complications can arise:

• Permanent central vision loss – Leading to legal blindness.
• Sub‑retinal fibrosis (scar tissue) – Irreversible damage preventing visual recovery.
• Geographic atrophy – Expansion of atrophic areas that further diminish visual field.
• Secondary cataract formation – From repeated intravitreal injections.
• Psychosocial impact – Increased risk of depression, reduced independence, and higher fall rates.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Age‑related macular degeneration (AMD). 2023.
2. World Health Organization. Global data on visual impairment 2022.
3. National Eye Institute (NEI). Genetics of AMD. 2022.
4. Centers for Disease Control and Prevention. Smoking and eye disease. 2021.
5. Cleveland Clinic. Optical Coherence Tomography (OCT) for AMD. 2023.
6. NEI Age‑Related Eye Disease Study 2 (AREDS2) – Clinical outcomes of anti‑VEGF therapy. 2020.
7. JAMA Ophthalmology. AREDS2 supplement effect on AMD progression. 2018.